W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Position of the Transparency Council

08 August, 2024

Position of the Transparency Council – Kuvan (sapropterin)

08 August, 2024

Position of the Transparency Council – Ultomiris (ravulizumab)

08 August, 2024

Position of the Transparency Council – Omvoh (mirikizumab)

08 August, 2024

Position of the Transparency Council – Zolgensma (onasemnogene abeparvovec)

08 August, 2024

Position of the Transparency Council – Ayvakyt (avapritinib)

01 August, 2024

Position of the Transparency Council – Daraprim

25 July, 2024

Position of the Transparency Council – on the validity of the qualification of the service Gyroscopic Stereotactic Teleradiotherapy (TSZ) using the novel ZAP-X device

25 July, 2024

Position of the Transparency Council – Cablivi (caplacizumab)

25 July, 2024

Position of the Transparency Council – Ilaris (canakinumab)

25 July, 2024

Position of the Transparency Council – Tecentriq (atezolizumab)

25 July, 2024

Position of the Transparency Council – Fintepla (fenfluramine)

17 July, 2024

Position of the Transparency Council – Agamree (vamorolone)

17 July, 2024

Position of the Transparency Council – Agamree (vamorolone)

17 July, 2024

Position of the Transparency Council – Lynparza (olaparib)

17 July, 2024

Position of the Transparency Council – Hemlibra (emicizumab)

17 July, 2024

Position of the Transparency Council – Opdivo (nivolumab)

17 July, 2024

Position of the Transparency Council – Cabometyx (cabozantinib)

10 July, 2024

Position of the Transparency Council – Glycosade

10 July, 2024

Position of the Transparency Council – Keytruda (pembrolizumab)

10 July, 2024

Position of the Transparency Council – Kanuma (sebelipase alfa)

04 July, 2024

Position of the Transparency Council – Prophylaxis of necrotizing enterocolitis (NEC) in premature infants with birth weight less than 1,500 g using a food for special medical use, a three-strain probiotic product that meets the criteria of the ESPGHAN recommendation

04 July, 2024

Position of the Transparency Council – Zynlonta (lonkastuximab thesirine)

27 June, 2024

Position of the Transparency Council – Acarizax

20 June, 2024

Position of the Transparency Council – on the appropriateness of issuing approvals for reimbursement of foodstuffs Foodstuffs for special nutritional use S.O.S. 10, S.O.S. 15, S.O.S. 20, S.O.S. 25

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑